Mitchell A. Jackson, MD

I would like to congratulate Mitch Jackson on his 100th Premium Channel column in OSN. Mitch’s entertaining approach to presenting cutting-edge techniques and technology in premium refractive surgery has always matched his ebullient personality.

As I am returning home from a recent premier eye surgical meeting in Belgium, I am reflecting on one of the lectures that hit close to home.

WASHINGTON — In this Healio Video Perspective from the American Society of Cataract and Refractive Surgery meeting, Mitchell A. Jackson, MD, discusses laser scleral microporation, a new presbyopia therapy soon going to FDA clinical trial.

At the recent ASCRS meeting in Washington, my fellow Abhi Guduru, MD, and I presented on “Quantifying postoperative satisfaction in patients with intraocular premium lenses” and were honored to share the value of lifestyle questionnaires.

Three years ago, tragedy struck my family with the loss of my brother due to metastatic lung cancer.

The FDA approved the first pharmacological drug for the treatment of presbyopia in October 2021. Vuity from Allergan is a once-daily 1.25% pilocarpine HCL ophthalmic solution with pHast technology.

In the field of ophthalmology and optometry, dry eye disease has been anything but delightful, fun or mesmerizing.

Nine years ago, it started at the Hawaiian Eye meeting, where the Healio/Ocular Surgery News editors paved the way for me to write this Premium Channel column. This is now my 94th column, and I will hit my 100th submission mid-year.

The time for premium IOLs has finally arrived, with many new and exciting options and fewer side effects than earlier-generation technology.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.